Efesovir
Small moleculeexperimental
Clinical trial activity
2 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Dec 1, 2013 (NCT02607449)
Timeline
Indications
Mechanism of action
- Hepatitis B virusINHIBITOR
Hepatitis B virus inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- fs-1
- fs-1
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05060705 | Phase 2 | Dec 31, 2021 | Scientific Center for Anti-infectious Drugs, Kazakhstan |
| NCT02607449 | Phase 3 | Dec 1, 2013 | Almaty City Tuberculosis Dispensary, Almaty, Kazakhstan, Government of Kazakhstan, Government of Kyrgyzstan, JSC Scientific Center for Anti-infectious Drugs, Karaganda State Medical University, Regional Anti-TB Dispensary of Karagandy Oblast, Kazakhstan, Scientific Center for Anti-infectious Drugs, Kazakhstan |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Scientific Center for Anti-infectious Drugs, Kazakhstan | Academic/Hospital | 2 | 2 | 2 | 2013 |
| Almaty City Tuberculosis Dispensary, Almaty, Kazakhstan | Academic/Hospital | 1 | 0 | 1 | 2013 |
| Government of Kazakhstan | Government | 1 | 0 | 1 | 2013 |
| Government of Kyrgyzstan | Government | 1 | 0 | 1 | 2013 |
| JSC Scientific Center for Anti-infectious Drugs | Academic/Hospital | 1 | 0 | 1 | 2013 |
| Karaganda State Medical University | Academic/Hospital | 1 | 0 | 1 | 2013 |
| Regional Anti-TB Dispensary of Karagandy Oblast, Kazakhstan | Academic/Hospital | 1 | 0 | 1 | 2013 |
7 organizations
Page 1 / 1